Milestone plans to initiate a Phase 3 study for the use of etripamil in Atrial Fibrillation with Rapid Ventricular Rate (AFib-RVR) in the first half of 2025. The company is strengthening its ...

Milestone Pharmaceuticals (MIST) provided a corporate update and outlined its strategic priorities for 2025. CARDAMYST for Paroxysmal ...

PDUFA date of March 27, 2025 for CARDAMYST™ (etripamil) nasal spray for Paroxysmal Supraventricular Tachycardia (PSVT)- Commercial capabilities ...

PDUFA date of March 27, 2025 for CARDAMYST (etripamil) nasal spray for Paroxysmal Supraventricular Tachycardia (PSVT) - Commercial capabilities build out in process, with proposed launch in PSVT targe ...

H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating and a price target of $25.00 on Milestone Pharmaceuticals, traded on NASDAQ under the ticker (NASDAQ:MIST). The stock has shown strong ...

A rapid heartbeat and shortness of breath could be signs of atrial fibrillation (AFib), an irregular heartbeat. Dr. Jim Stone, a cardiac electrophysiologist at North Medical Center in Tupelo, helps ...

A recent Brazilian study published in Nature Cardiovascular Research has highlighted promising pathways for preventing and ...

BACKGROUND: Hypertensive disorders of pregnancy (HDP) are a major cause of maternal morbidity and mortality and are associated with acute cardiac events in the peripartum period, as well as ...

In February 2024, Corewell Health introduced pulsed field ablation, a treatment procedure significantly safer than previous AFib treatments, at several of its Michigan hospitals. PFA applies a ...

Background Iron deficiency (ID) is common in patients with atrial fibrillation/flutter (AF), but its prognostic implications and optimal diagnostic criteria, particularly in those with and without ...

The safety of abelacimab as compared with a direct oral anticoagulant in patients with atrial fibrillation is unknown. Patients with atrial fibrillation and a moderate-to-high risk of stroke were ...